№ files_lp_3_process_9_24208
File format: docx Character count: 11279 File size: 6690 KB
High-throughput sequencing and methylation profiling of plasma and buffy coat samples quantify ctDNA fraction, identify gene-level alterations, and associate these molecular features with progression and survival outcomes in metastatic prostate cancer.
Year: 2026
Region / City: Not specified
Topic: Cancer genomics, epigenetics, prostate cancer
Document type: Supplementary material
Institution: Not specified
Authors: Chennan Li et al.
Target audience: Researchers in oncology and molecular biology
Sample type: Plasma and buffy coat
Methods: ctDNA sequencing, 5mC/5hmC methylomics, clonal reconstruction
Timepoints: Baseline, restaging, progression, off-study
Genes analyzed: AR, BRCA2, erythroid markers, platelet/megakaryocyte markers, globins
Data included: Sequencing metrics, methylation percentages, gene-level events, survival analysis
Associated figures: 8 supplementary figures, 2 supplementary tables
Statistical analyses: Spearman correlation, Kruskal-Wallis test, Mann-Whitney U test, Kaplan-Meier survival estimates, log-rank test
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
NHS Genomic Medicine Service ctDNA Testing for NSCLC and Breast Cancer Provision for 2025/26
Year: 2025
Region / City: North West NHS GMS region
Topic: ctDNA testing for NSCLC and breast cancer
Document Type: Notification
Organization: NHS England
Author: Genomics Unit
Target Audience: NHS Trusts
Period of Action: 2025/26 financial year
Approval Date: 7 November 2025
Date of Changes: N/A
Context: Notification regarding the continuation and expansion of ctDNA testing for lung and breast cancer in the North West NHS region for the 2025/26 financial year.
NW GLH ctDNA ESR1 Pathway SOP
Year: 2023
Region / City: Manchester
Topic: ctDNA Testing, ESR1 Pathway
Document Type: Standard Operating Procedure
Organization: North West Genomic Laboratory Hub (NWGLH)
Author: Not specified
Target Audience: NHS Trusts, Clinical Teams
Action Period: Ongoing
Approval Date: Not specified
Revision Date: Not specified
Number of patients with evaluable blood samples and ctDNA detection across studies from 2021–2024
Year: 2021–2024
Authors: Cabalag, Hofste, Morimoto, Ng, Ococks, Kelly, van den Ende, Veschoor, Wang, Yue
Number of patients: 20–111 per study
Type of document: Supplementary table
Data points: ctDNA detection at baseline, after NAT, and after surgery
Study population: Patients undergoing ctDNA tests
Measurement type: Evaluable blood samples and ctDNA presence
Context: Scientific supplementary table presenting the distribution of patients with evaluable blood samples and ctDNA detection results across multiple studies in clinical research
Topics: 5mC5hmC methylomics ctDNA